title: A randomized trial assessing the utility of a test-dose program with taxanes.
abstract: OBJECTIVE
  Taxanes are commonly used anticancer agents with a potential of producing an allergic or hypersensitivity reaction (HSR). We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel.
  
  
  METHODS
  Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug wastage due to a HSR.
  
  
  RESULTS
  Two hundred and eighteen patients were randomized from three different treatment sites. The overall incidence of HSR was 6.5% and there was no significant difference in the incidence of HSR in either group. The mean HSR severity grade was 2.8 for patients without a test dose and 2.3 for those receiving a test dose. There was, however, a reduction in the wastage of taxane in the test dose arm. Wastage avoided in the test dose arm was $1573 per patient who had a HSR and $104 per patient treated with a taxane.
  
  
  CONCLUSIONS
  Although a test dose may not reduce the severity of a HSR with the administration of a taxane, it does reduce the cost associated with drug wastage.
authors.affiliation: Texas Tech University Health Sciences Center School of Pharmacy, Lubbock & Dallas, TX, USA.
authors.forename: B L
authors.initials: BL
authors.lastname: Stanford
authors.forename: S R
authors.initials: SR
authors.lastname: Shah
authors.forename: E E
authors.initials: EE
authors.lastname: Ballard
authors.forename: C A
authors.initials: CA
authors.lastname: Jumper
authors.forename: I
authors.initials: I
authors.lastname: Rabinowitz
authors.forename: J E
authors.initials: JE
authors.lastname: Dowell
authors.forename: W C
authors.initials: WC
authors.lastname: Hunt
authors.forename: J A
authors.initials: JA
authors.lastname: Krieger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D003363:Cost Control; D000077143:Docetaxel; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel